XSWX
YPSN
Market cap5.74bUSD
Oct 09, Last price
362.20CHF
1D
-0.77%
1Q
1.28%
Jan 2017
96.32%
IPO
387.52%
Name
Ypsomed Holding AG
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Ypsomed Holding AG, along with its affiliates, specializes in the design, production, and sale of advanced injection and infusion delivery systems for pharmaceutical and biotechnology enterprises. The company structures its activities into two main divisions: Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment offers a broad array of innovative injection devices, including pen, auto, patch, and wearable injectors, as well as other smart medical technologies, all marketed under the YDS brand. Meanwhile, the Ypsomed Diabetes Care division is dedicated to providing vital products for diabetes management, such as insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, and various daily essentials, all sold under the mylife brand. Furthermore, the company extends its services to include precision turned parts and contract manufacturing. Its diverse product range is distributed through strategic partnerships with biotech and pharma companies, its own distribution infrastructure, and independent distributors. Established in 1984 and headquartered in Burgdorf, Switzerland, Ypsomed Holding AG maintains a significant presence across Switzerland, Europe, North America, and other international regions.
Related entities
Subsidiaries
Ypsomed AG
Key people
Chairman of the Board of Directors · since 2014
Paul Fonteyne
Non-Executive Director · since 2018
Headquarters & legal address
Brunnmattstrasse 6
Burgdorf, BE 3400
CH
Burgdorf, BE 3400
CH
Other language
Ypsomed Holding Inc.
Other language
Ypsomed Holding SA
Valuation
Title CHF in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||